Company Info for lewin.com | IcebreakerMembers
Energetic healthcare leader with operations and public health background. Multiple years of hands-on experience analyzing real world data, particularly Medicare, Medicaid, and commercial claims data, to measure the impact of policies and programs on the use and cost of health care services and quality of care. Lori has led complex analyses that assist partners and clients, including the Center for Medicare and Medicaid Innovation (CMMI), in fulfilling their strategies and understanding the impact of value-based care; her work has covered ACO, BPCI-A, and global budget models. She has a master's degree in Epidemiology from the Columbia University, Mailman School of Public Health and a master's degree in Public and Non-Profit Management and Policy, Public Finance, from New York University. 
Chief of Strategic and Performance Innovation for the San Francisco Department of Public Health (SFDPH), partnering with its executive team to lead the strategic direction of SFDPH. Also establishes direction for the SFDPH Kaizen Promotion Office and departmental improvement partners, coordinating department-wide lean and performance improvement activities while fostering an organizational culture of improvement.
Previously served as Associate Chief Medical Officer for Quality and Lean at Zuckerberg San Francisco General and is a UCSF Clinical Professor, and is passionate about improving health and delivering high quality care with compassion and respect. Experienced in leading, coaching, and teaching mission- and data-driven executive and interdisciplinary teams in quality improvement, health equity improvement, strategic deployment, Lean transformation, A3 Thinking problem solving, and care for vulnerable populations. Educational background in health policy and management, master lean certified, and board certified in internal medicine. 
Experienced policy chief, GC and strategic advisor to tech startups, trial and appellate litigator, former White House senior lawyer, and law firm partner with 20+ years of complex regulatory, oversight, and deals experience, with emphasis on blockchain, energy, climate tech, and healthcare sectors. First-chair veteran of >95 congressional investigations and 62 hearings, high-stakes crisis management and strategic comms efforts in the national news, dozens of VC investment and partnership deals across emerging tech, and author of dozens of briefs in federal and state courts, including the U.S. Supreme Court. 
PAST LIFE: Decided to craft a sabbatical of sorts. I do ascribe to the concept of "lifelong learning." Over the next 12-18 months, I will pursue advanced training in structural interventions and an executive MBA.
I decided to go back for an additional year of training to hone my structural interventional skill set, which will include TAVR, mitraclip, tricuspid valve interventions, ASD/PFO, Watchman and perivalvular leaks, as well as more complex coronary and periperheral vascular techniques.
Additionally, I will start an executive MBA at Duke University (its like going back home) with a particular focus on entrepreneurship and innovation. I do believe that physicians need to become more involved in driving healthcare and must ensure that we have an influential seat at the table. No more talking over us!
I am not sure where the additional training will take me but I do consider myself blessed enough to be able to take advantage of these opportunities.
FORWARDS EVER, BACKWARDS NEVER!
FORMER LIFE: Interventional Cardiologist- Worked at a 250 bed hospital in a rural area ~ 40 miles north of Kansas City as an attending interventional cardiologist for 3.5 years. l am experienced in general cardiology care (ECHO, stress test, consultative care), cardiac catheterization and complex PCI.
FORMER FORMER LIFE: Physician- scientist with experience in a number of molecular biology techniques including, but not limited to, cell culture, westernblot, retroviral and adenoviral generation, PCR, RNA, cDNA, ELISA, etc. My PhD research focused on the regulation of a cleaved product of Tie2, known as soluble Tie2, and its role and regulation in the Tie2-Angiopoietin system and pathological angiogenesis. Clinically, I will pursue a career as a cardiologist and vascular medicine special with particular emphasis on peripheral interventions. From a research standpoint, I am a vascular biologist with interest in therapeutic angiogenesis. 
